AlphaYouJZ
Insider selling
Jonathan Zalevsky sold $336K of Nektar Therapeutics (NKTR) stock
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 5,538 shares of NKTR stock worth $336K, per an SEC Form 4 filed Jun 17, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Jun 15, 2026, 2 days before it was made public.
NKTR has moved +9.3% since the trade date, from $61.15 to $66.84 (Sep 21, 2026 close).
- Traded
- Jun 15, 2026
- Disclosed
- Jun 17, 2026
- Filing delay
- 2 days
- Price since
- +9.3%
- Role
- Chief R&D Officer
- Source
- SEC Form 4
More NKTR insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.